Consistent with its regulatory function of the levels of endogenous molecules, high UGT2B17 may deplete intracellular metabolites leading to aberrant cell signalling and dysregulated cell functions,22 which could favour progression in untreated CLL cases and subsequent drug resistance in treated patients. This evidence concerns the gene UGT2B17 and B-cell chronic lymphocytic leukemia.